|Day Low/High||12.60 / 12.94|
|52 Wk Low/High||7.83 / 11.88|
This bank is strong in the areas that would benefit the most from Trump's reforms.
Shares are down for Unilife, which doesn't meet our portfolio criteria.
We beat the benchmark Russell 2000 for the quarter, and we await a busy week on the economic front.
Synovus and Huntington Bancshares are both trading up today, tracking the rise of 10-Year Treasury yields.
Bearish names dominate this week and financials in particular.
We are keeping an eye on rate-sensitive names for possible buying opportunities, as stocks fell around 1.5% this week.
We picked up more Abraxas Petroleum on weakness, while the market rebounded slightly after the FOMC announced the anticipated quarter-point rate hike.
Shareholders of Synovus Financial and Huntington Bancshares will qualify for payouts this week.
We bulked up on Abraxas Petroleum and Yamana Gold on weakness, as the markets pulled back and investors positioned for next week’s FOMC meeting.
We booked some profits in Huntington Bancshares and Builders FirstSource, while markets digested the likelihood of a March rate hike.
We believe the prudent move is to lock in some of these gains.
The company is our second-largest holding, and we believe it’s prudent to take profits once we’ve doubled our investment.
We opened a new position in Abraxas Petroleum on its above-average growth potential, as stocks faced selling pressure this week.
Jim Cramer is bullish on Incyte, Skyworks Solutions, Western Digital, Constellation Brands and more.
This market may be cheaper than it looks, especially if companies can keep delivering on the earnings front, says Jim Cramer.
- The multi-year contract renewal includes use of Black Knight's MSP platform to manage Huntington's mortgage and home equity loans on one platform.
We closed out our position in OraSure Technologies for an average gain of 105% gain.
We used some of the proceeds to boost our stake in Jive Software this week. In addition, we initiated a position in drug-delivery system developer, Antares Pharma.
The central bank exempted mid-sized companies from the "qualitative" part of stress tests that determine whether the companies can pay dividends and buy back stock in the coming year.
We used a price decline to add to our position in TherapeuticsMD this week.
The company saw solid growth in commercial and industrial loans and deposits.
We'll be listening tomorrow for management’s 2017 interest rate outlook.
The advisers stand to benefit if the sector sees more deal activity under Trump.
We’d look to purchase Builders FirstSource, Jive Software and TherapeuticsMD on near-term declines.